The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study
-
Published:2024-03
Issue:
Volume:
Page:
-
ISSN:1526-8209
-
Container-title:Clinical Breast Cancer
-
language:en
-
Short-container-title:Clinical Breast Cancer
Author:
Chen Xi, Wei XinyuORCID, Yao Peizhuo, Liu Yanbin, Guan Haitao, Kang Huafeng, Liu Di, Diao Yan, Ma Xiaobin, Min Weili, Shan Changyou, Zhao Yang, Zhao Fang, Chen Yuanyuan, Xiao Dong, She Qing, Liu Youhuai, Zhang Yinbin, Zhang Shuqun
Reference34 articles.
1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. Accessed December 13, 2022. https://seer.cancer.gov/archive/csr/1975_2014/. 2. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†;Cardoso;Ann Oncol,2019 3. NCCN clinical practice guidelines in oncology: breast cancer, version 5. 2020;Gradishar;J Natl Compr Canc Netw,2020 4. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019;Burstein;Ann Oncol,2019 5. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States;Mougalian;Cancer,2015
|
|